LANCET Journal

Overview
Identity
Ver todos

publication venue for

Galectin-9 and TIM-3 as prognostic cancer biomarkers in sleep apnoea: an observational, longitudinal, multicohort study. 1-7. 2024
General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants. 851-863. 2024
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. 1-20. 2024
Spain facing the challenge of regulating unhealthy food advertising. 1493-1493. 2023
Risk stratification and health inequalities in women with acute coronary syndrome: time to move on. 710-711. 2022
GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.. 387-397. 2021
Managing NSTEMI in older patients. 370-371. 2021
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.. 957-980. 2021
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. 1-9. 2020
Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. 1511-1524. 2020
Hip attack for hip fractures: is ultra-early surgery neccesary? . 661-662. 2020
The need for an independent evaluation of the COVID-19 response in Spain. 529-530. 2020
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.. 143-155. 2019
Refractive surgery. 2085-2098. 2019
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.. 2428-2438. 2019
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. 143-155. 2018
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.. 1499-1515. 2017
Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1,479 population-based measurement studies with 19.1 million participants. . 37-55. 2017
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults.. 1-16. 2017
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.. 1377-1397. 2016
Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. 1-19. 2016
Worldwide trends in diabetes since 1980: pooled analysis of 751 population-based measurement studies with over 4.4 million participants. . 1-10. 2016
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-rit. 775-784. 2015
Tamoxifen and the uterus and endometrium. 1-2. 2015
Ebola: an open letter to European governments.. 1259-1259. 2014
National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants.. 557-567. 2011
National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. 568-577. 2011
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.. 340-345. 2010
Biko to Guantanamo: 30 years of medicalinvolvement in torture. 823-823. 2007
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for inicial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. 476-482. 2006
GSTM1 null genotype and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. 649-659. 2005
Effect of HAART on liver-related mortality in patients with HIV/HCV coinfection. 570-580. 2004
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. 51-62. 2004
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. 1267-1274. 2003
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. 1267-1274. 2003
Antifungal drug resistance to azoles and polyenes. 550-563. 2002
Leishmania in discarded syringes from intravenous drug users. 1124-1125. 2002
Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial.. 1915-1924. 2001
Efficacy and safety of tenecteplase in combination with enoxaparin,abcximab,or unfranctioned heparin:the ASSENT-3 randomised trial in acute myocardial infarction.. 605-613. 2001
Reperfusion theraphy for acute myocardial infarction with fibrinolytic theraphy and platelet glycoprotein IIb/IIIa inhibition: the Gusto V radomised trial.. 1905-1914. 2001
End-of-life decisions in neonatal intensive care: physicians. 2112-2118. 2000